|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 48, 1353-1361, June 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology




,**
* Netherlands Organization for Applied Scientific Research-Quality of Life, Department of Biomedical Research, Gaubius Laboratory, Leiden, The Netherlands
Department of General Internal Medicine, Endocrinology, and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
** Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
Departments of Molecular Genetics and Pathology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
Published, JLR Papers in Press, March 5, 2007.
1 To whom correspondence should be addressed. e-mail: m.westerterp{at}lumc.nl
| ABSTRACT |
|---|
|
|
|---|
35% (P < 0.05). We speculated that apoC-I binds FFA extracellularly, thereby preventing cell association of FFA. We showed that apoC-I was indeed able to mediate the binding of oleic acid to otherwise protein-free VLDL-like emulsion particles involving electrostatic interaction. We conclude that apoC-I binds FFA in the circulation, thereby reducing the availability of FFA for uptake by cells. This mechanism can serve as an additional mechanism behind the resistance to obesity and the cutaneous abnormalities of APOC1+/+ mice.
Supplementary key words lipoprotein macrophage skin lipoprotein lipase triglyceride
Abbreviations: acat1/, acyl-CoA:cholesterol acyltransferase 1-deficient; apoC-I, apolipoprotein C-I; APOC1+/+, homozygous human apoC-I transgenic; APOC1+/0, hemizygous human apoC-I transgenic; apoc1/, apoC-I-deficient; BMIPP, 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid; CE, cholesteryl ester; dgat1/, acyl-CoA:diacylglycerol acyltransferase 1-deficient; FAR, fatty acyl-CoA reductase; FPLC, fast-performance liquid chromatography; GAG, glycosaminoglycan; lpl/, LPL-deficient; LPS, lipopolysaccharide; scd1/, stearoyl-CoA desaturase 1-deficient; TG, triglyceride
| INTRODUCTION |
|---|
|
|
|---|
6 mg/dl and is present mainly on chylomicrons, VLDLs, and HDLs (2). To study the role of apoC-I in lipoprotein metabolism, we have generated apoC-I-deficient (apoc1/) (3), apoe/apoc1/ (4), human transgenic hemizygous apoC-I (APOC1+/0), homozygous apoC-I (APOC1+/+) (5), and apoe/APOC1+/0 mice (6). Endogenous apoC-I expression in wild-type and apoe/ mice and overexpression of human apoC-I in wild-type and apoe/ mice have consistently led to increased triglyceride (TG) levels, mainly caused by the apoC-I-induced inhibition of LPL (68). In addition, APOC1+/+ mice exhibit reduced adipose tissue stores and are protected against obesity as induced by diet and on an ob/ob background (9). Furthermore, APOC1+/+ mice lack subdermal fat, show decreased levels of wax esters and TG in their skin and cutaneous abnormalities, including epidermal hyperplasia/hyperkeratosis, and atrophic sebaceous and meibomian glands. These abnormalities are reflected by a dry skin, crusts around the eyes, hair loss at a young age, and lack of sebum and meibum production (10). Sebum is suggested to prevent water loss from the skin (10), whereas meibum prevents evaporation of the aqueous component of the tear (11), both by formation of a lipid layer on the fluid in the skin or of the tear. Reduced systemic LPL activity in APOC1+/+ mice contributes to diminished availability of FFA for esterification into TG for storage in adipose tissue and into TG and wax esters that are major components of sebum in the skin (10). However, it is likely that apoC-I also interferes with FFA availability by direct binding to FFA. APOC1+/+ mice have 4-fold increased levels of FFA in plasma compared with their wild-type littermates (10), and the uptake of the FFA analog 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) by adipose tissue is reduced in APOC1+/+ob/ob mice compared with their ob/ob littermates (9). The hypothesis that apoC-I directly interacts with FFA is further supported by our recent finding that apoC-I binds to lipopolysaccharide (LPS), mainly as the consequence of the positively charged lysine (K) residues in the LPS-binding motif KVKEKLK of apoC-I, which presumably interact with the negatively charged lipid A moiety of LPS (12). As FFAs are also negatively charged at physiological pH, the binding properties of apoC-I to FFAs might parallel those to LPS.
Therefore, the aim of this study thus was to evaluate whether locally produced apoC-I reduces FFA esterification in cells by reducing FFA availability as a consequence of extracellular association with FFA. We showed first by skin transplantation from APOC1+/+ mice to wild-type mice that the effects of apoC-I on FFA esterification in the skin were local, as the skin phenotype did not change upon relief of systemic LPL inhibition. Then, we demonstrated that apoC-I reduced the esterification of FFA into TG and cholesteryl esters (CEs) in macrophages, cells that naturally accumulate lipids, as related to direct extracellular binding of apoC-I to FFA. The effects of apoC-I on FFA binding and intracellular esterification were dependent on the positively charged lysine residues in the KVKEKLK motif of apoC-I. From these data, we conclude that apoC-I binds to FFA as a consequence of its lysine-rich sequence, which results in reduced influx of FFA into cells by direct inhibition of cellular FFA influx.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Skin transplantation
Donor mice were euthanized, dorsal skin (dermis and epidermis) was removed, and excess fat and blood vessels were stripped off. The recipient mice were anesthetized with Hypnorm (1:20, 120 µl/mouse; Janssen Pharmaceutica, Tilburg, The Netherlands). Two circular pieces of dorsal skin,
1 cm in diameter, were aseptically removed down to the pannus carnosus. The donor skin was cut to fit the transplant bed and held in place using six sutures. The transplant was covered with Op-Site (Smith and Nephew, Hull, England) and protected by gauze held in place with 3M surgical foam tape. The tape was kept on for at least 2 weeks. APOC1+/+ mice were transplanted with skin grafts from wild-type mice, and inversely, wild-type mice were transplanted with skin grafts from APOC1+/+ mice. As a control, wild-type mice were transplanted with skin grafts from wild-type mice. Six weeks after transplantation, mice were euthanized, and pieces of skin tissue were fixed in 10% neutral-buffered formalin. Subsequently, skin tissue was embedded in paraffin, and 3 µm sections were made and routinely stained with hematoxylin-phloxine-saffron.
ApoC-I mutant synthesis
An apoC-I mutant in which the lysines of the C-terminal KVKEKLK sequence, involved in the LPS binding properties of apoC-I, were replaced by alanines (A) (giving AVAEALA) was synthesized by the Protein Chemistry Technology Center at the University of Texas Southwestern Medical Center (Dallas, TX) (purity
95%) (12).
Macrophage studies
Apoc1/ and wild-type mice were injected intraperitoneally with 1 ml of 3% Brewer's thioglycollate medium (Difco) to induce the infiltration of macrophages. After 4 days, macrophages were isolated, plated, and cultured for 24 h. Apoc1/ and wild-type macrophages were loaded with 50 µg/ml acetylated LDL for 48 h to enlarge the intracellular lipid pool. Subsequently, cells were washed and incubated with 0.1 M oleic acid (Sigma, St. Louis, MO), 2 µCi/ml [3H]oleic acid (Amersham Biosciences, Little Chalfont, UK), and 0.1% fatty acid-free BSA (Sigma) for 0, 15, 30, 45, 75, and 120 min. Alternatively, wild-type macrophages were incubated for 45 min with and without 5 mM apoC-I or apoC-I mutant, 5 mM oleic acid, 0.1 µCi/ml [3H]oleic acid, and 0.05% fatty acid-free BSA.
Then, all cells were lysed in water, and the cellular protein content (13) as well as cellular 3H activity were measured, with the ratio 3H activity/cell protein indicating the association of [3H]oleic acid with the cells. To determine the extent of [3H]oleic acid esterification into TG and CE in apoc1/ and wild-type macrophages, cellular lipids were extracted according to Bligh and Dyer (14) and separated by high-performance thin-layer chromatography. After staining with color reagent [5 g of MnCl2·4H2O, 32 ml of 9597% H2SO4 added to 960 ml of CH3OH/H2O (1:1, v/v)], the bands corresponding to CE and TG were scraped off the plates, counted for 3H activity, and corrected for cellular protein content.
Analysis of mouse plasma
Blood from wild-type, APOC1+/0, and APOC1+/+ mice was collected by tail bleeding into chilled paraoxon (Sigma)-coated capillary tubes to prevent ongoing in vitro lipolysis. The tubes were placed on ice and centrifuged at 4°C, and the obtained plasma was snap-frozen in liquid nitrogen and stored at 20°C. To determine the association of apoC-I and FFA with VLDL, plasma was injected onto a Superose 6 HR 10/30 column, and the obtained fractions were assayed for FFA using the NEFA-C kit (Wako Chemicals, Neuss, Germany) and for apoC-I using the apoC-I ELISA as described below.
Preparation of TG-rich VLDL-like emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described previously (15, 16). In short, 100 mg of lipid at a weight ratio of egg yolk phosphatidylcholine-triolein-lysophosphatidylcholine-cholesteryl oleate-cholesterol of 22.7:70:2.3:3.0:2.0 was sonicated at 10 µm output using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK). An emulsion fraction containing 80 nm emulsion particles was obtained by consecutive density gradient ultracentrifugation steps and used for subsequent experiments. The TG content of the emulsions was determined using the commercially available enzymatic kit 1488872 (Roche Molecular Biochemicals, Indianapolis, IN). Emulsions were stored at 4°C under argon and were used within 14 days.
ApoC-I FFA binding experiments
ApoC-I (5, 10, 20, and 40 mg/dl) or the apoC-I mutant (9.7 mg/dl; molar concentration equal to 10 mg/dl apoC-I) was associated with emulsion particles (6 mM TG) by incubation in PBS (pH 7.4) for 30 min at 37°C. Subsequently, 2 mM oleic acid complexed with 5 mg/ml fatty acid-free BSA in PBS (pH 7.4) was added (total volume, 80 µl) and was allowed to associate with the (apoC-I-laden) emulsion particles for an additional 30 min at 37°C. To determine the association of oleic acid with the apoC-I-laden emulsion particles, the mixture was injected onto a Superose 6 HR 10/30 column (Akta System; Amersham Pharmacia Biotech, Piscataway, NJ) and eluted at a constant flow rate of 50 µl/min PBS, 1 mM EDTA (Sigma), pH 7.4. During fast-performance liquid chromatography (FPLC), fractions of 50 µl were collected and assayed for apoC-I using the apoC-I ELISA and for FFA as described above.
ApoC-I ELISA
The apoC-I concentration in FPLC fractions and in plasma from APOC1+/0 and APOC1+/+ mice was quantified using a human apoC-I sandwich ELISA as described previously (6). In short, a polyclonal goat anti-human apoC-I antibody (Academy Biomedical Co., Houston, TX) was coated overnight onto Costar medium binding plates (Corning, Inc., New York, NY) (dilution, 1:10,000) at 4°C and incubated with the diluted pool of FPLC fractions containing the emulsion particles (dilution, 1:10,000) or mouse plasma (dilution, 1:16,000) for 2 h at 4°C. Subsequently, HRP-conjugated polyclonal goat anti-human apoC-I antibody (dilution, 1:500; Academy Biomedical Co.) was added and incubated for 2 h at room temperature. After extensive washing, HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 20 min at room temperature. Human apoC-I (Labconsult, Brussels, Belgium) was used as a standard.
Statistics
All data are presented as means ± SD. The general linear model was used to compare the trends between the [3H]oleate ester generation curves of apoc1+/+ (wild-type) and apoc1/ macrophages. The Mann-Whitney nonparametric test for two independent samples was used to define differences between data sets from experimental groups. The criterion for significance was set at P < 0.05. Statistical analyses were performed using SPSS 11.5 (SPSS, Inc., Chicago, IL).
| RESULTS |
|---|
|
|
|---|
|
First, we examined the effect of endogenous apoC-I on the esterification of oleic acid into CE and TG using apoc1/ and apoc1+/+ (wild-type) macrophages. Although the association of [3H]oleic acid with cells of both genotypes increased time-dependently, the cell association was consistently
25% lower in apoc1+/+ versus apoc1/ macrophages (P < 0.05) (Fig. 2
). After separation of intracellular lipids, it appeared that this decrease was reflected by a decreased esterification of [3H]oleic acid into both TG (Fig. 3A
) and CE (Fig. 3B). After 120 min of incubation, apoC-I decreased the esterification of [3H]oleic acid into TG by 36% (P < 0.05) (Fig. 3A) and the esterification of [3H]oleic acid into CE by 35% (Fig. 3B). Furthermore, the trends of the curves for the esterification of [3H]oleic acid into TG and CE were both significantly different between apoc1/ and apoc1+/+ macrophages (P < 0.05), indicating that apoC-I expression reduced the overall rate of oleic acid esterification (Fig. 3A, B).
|
|
|
We first determined the distribution of FFA and apoC-I over lipoproteins in plasma of wild-type, APOC1+/0, and APOC1+/+ mice. In wild-type mice, the majority of FFA is bound to serum albumin and only a minor fraction associates with VLDL (<5%). In APOC1+/0 and APOC1+/+ mice, serum albumin-associated FFA levels increased, indicating increased FFA saturation of serum albumin. In addition, the association of FFA with VLDL/IDL was highly increased in APOC1+/0 mice (
25%) and APOC1+/+ mice (
62%), corresponding with increased apoC-I levels on VLDL/IDL (7.9 and 59.1 mg/dl in APOC1+/0 and APOC1+/+ mice, respectively) (Fig. 5
). Thus, these results suggest that apoC-I bridges FFA to VLDL/IDL particles.
|
|
| DISCUSSION |
|---|
|
|
|---|
The explanation that LPL inhibition may underlie the phenotype of the APOC1+/+ mouse regarding cutaneous abnormalities and protection against obesity is supported by the findings that adipose tissue-specific LPL-deficient (lpl/) mice are protected against obesity on the ob/ob background and that whole body lpl/ pups lack, in their short life span of only 18 h, subcutaneous fat (19, 20). Thus, reduced LPL activity accounts for reduced adipose tissue stores. Although no effects on the skin of lpl/ mice can be studied as a result of the short life span of lpl/ pups (19), LPL is expressed in the dermal layer (21) and may affect FFA uptake in the skin. Thus, reduced LPL activity may, at least partially, explain the reduced obesity, the lack of subcutaneous fat, and the cutaneous abnormalities in APOC1+/+ mice.
Several lines of evidence indicate that an additional mechanism can explain the reduced FFA uptake by adipose tissue and skin. For example, the uptake of the FFA analog BMIPP by adipose tissue was reduced by human apoC-I expression on the ob/ob background (9) and plasma FFA levels are increased in APOC1+/0 and APOC1+/+ mice compared with wild-type mice (6, 10). As the apoC-I propeptide contains a signal peptide, resulting in the secretion of newly synthesized apoC-I from cells (18), apoC-I may interact with FFA extracellularly. Furthermore, apoC-I binds to the LPS, presumably as a consequence of an electrostatic interaction between the negatively charged phosphate groups in the lipid A moiety of LPS and the four positively charged lysine residues in the LPS binding motif KVKEKLK of apoC-I (12). Similarly, FFAs contain negatively charged carboxyl groups at physiological pH, suggesting that apoC-I might bind to FFAs in a similar manner. Therefore, we hypothesized that apoC-I prevents the influx of FFAs into cells as a result of binding to FFAs in plasma.
We first investigated whether the cutaneous abnormalities of APOC1+/+ mice are caused by local apoC-I production by performing skin transplantation studies. These studies showed no effects on the phenotype of the skin grafts, indicating that apoC-I reduced lipid entry into the skin and caused the cutaneous abnormalities of the APOC1+/+ mice via local effects, rather than via inhibition of systemic LPL activity. We then investigated whether apoC-I, either synthesized endogenously or added exogenously, can affect the esterification of extracellularly added oleic acid in cells. We used macrophages that naturally accumulate lipids and can infiltrate both the skin (10) and adipose tissue (17). It appeared that both endogenous and exogenous apoC-I reduced the association of [3H]oleic acid with macrophages, which was reflected by a decreased esterification of [3H]oleic acid into TG and CE. The finding that the incorporation of [3H]oleic acid into TG was greater than into CE can be explained by the presence of three esterified fatty acid chains in TG versus one in CE. These effects of apoC-I were dependent on the positively charged lysine residues in the LPS binding element KVKEKLK of apoC-I, as the apoC-I mutant, containing neutral alanine residues instead (AVAEALA), was ineffective.
Based on these findings, we speculated that the apoC-I-mediated reduction of FFA influx into cells would lead to decreased intracellular FFA levels and increased extracellular FFA levels in plasma. To gain more insight into the validity of such a mechanism, we investigated whether the presence of apoC-I on particular lipoproteins would cause this effect, as apoC-I in plasma is mainly bound to lipoproteins (2). In plasma from APOC1+/0 and APOC1+/+ mice, a large fraction of FFA appeared to be associated with VLDL (25% and 62%, respectively), suggesting that apoC-I is able to bridge FFA to VLDL. Subsequent in vitro experiments indeed showed that apoC-I, associated with VLDL-like TG-rich emulsion particles, bound to oleic acid dose-dependently, also dependent on the positively charged lysine residues in the LPS binding element KVKEKLK of apoC-I.
Collectively, these data indicated that apoC-I on VLDL binds to FFA in the circulation, thereby preventing the uptake and subsequent esterification of FFA by cells, which is dependent on the lysine residues in the LPS binding element KVKEKLK of apoC-I. The positive lysine residues contribute to the high isoelectric point of apoC-I (6.5) (22), which decreases to 4.8 upon replacement by neutral alanine residues (12). In fact, the isoelectric point of apoC-I is the highest of all known apolipoproteins (22); therefore, we postulate that this property to bind to FFA is specific for apoC-I and completely dependent on the electrostatic interaction between apoC-I and FFA.
We previously found that apoC-I can directly inhibit LPL activity (6). Our present finding that apoC-I binds to FFA suggests that apoC-I may also interfere with LPL activity via product inhibition. Indeed, in vitro studies have demonstrated that FFAs abolish the LPL-stimulating effects of apoC-II (23) and impede binding of LPL to its substrate, lipid droplets (24, 25). In addition, FFAs have been demonstrated to displace LPL from cultured endothelial cells in vitro (26) and have been suggested to dissociate LPL from its binding to endothelial proteoglycans if FFAs are more rapidly generated than used by the local tissue (27). In fact, the positively charged amino acid residues arginine (R) and lysine (28, 29) within the RLTRKRGLK motif of apoB appeared to be required for the association of VLDL/LDL with the cell surface glycosaminoglycans (GAGs) on the endothelium, where LPL is also located (30, 31). Conversely, negatively charged FFAs have been demonstrated to disrupt the binding of apoE-supplemented TG emulsions bound to heparin-agarose, as a model for cell surface heparan GAG, in vitro (32). Because binding of apoC-I to FFA depends on the presence of the positively charged lysine residues within the KVKEKLK motif of apoC-I, the electrostatic interaction of negatively charged FFAs associated with these positively charged lysine residues may shield the positively charged apoC-I, thereby decreasing its affinity for the GAG. This might also explain the apoC-I-induced LPL inhibition in APOC1+/0 and APOC1+/+ mice.
In addition to APOC1+/+ mice, stearoyl-CoA desaturase 1-deficient (scd1/) and acyl CoA:diacylglycerol acyltransferase 1-deficient (dgat1/) mice show cutaneous abnormalities and atrophic sebaceous glands, lack sebum and meibum production, and are protected against obesity on the ob/ob background (scd1/), in diet-induced obesity (dgat1/), or when bred on the Agouti yellow background (dgat1/) (3337). Furthermore, acyl-CoA:cholesterol acyltransferase 1-deficient (acat1/) mice show decreased sebum production and lack meibum production (11). The mechanisms underlying these findings in the various mouse models may share similarities. ApoC-I binds to FFAs in plasma, thereby preventing the cellular uptake of FFAs (this study), and SCD1 is the rate-limiting enzyme in the biosynthesis of MUFAs (35). Overexpression of apoC-I and deficiency of SCD1 thus both result in reduced levels of intracellular FAs. DGAT1 and ACAT1 catalyze the rate-limiting steps of TG and CE synthesis, respectively, exhibit wax synthase activity (38, 39), and are downregulated when intracellular FFAs are scarce (40, 41). We thus postulate that apoC-I reduces the availability of FFA substrate for esterification into TG by DGAT1 in adipose tissue, contributing to decreased development of obesity, and into TG by DGAT1 and CE by ACAT1 in macrophages, as observed in this study. Furthermore, apoC-I reduces the esterification of FFAs into wax esters by DGAT1 and ACAT1 in the skin, contributing to decreased sebum and meibum production. In fact, FFAs are first converted to fatty alcohols catalyzed by fatty acyl-CoA reductase 1 and 2 (FAR1 and FAR2) in the sebaceous or meibomian gland and subsequently esterified into wax esters catalyzed by wax synthase enzymes, also including acyl-CoA:monoacylglycerol acyltransferase 1 and 2, DGAT2, and ACAT2 (39, 42). ApoC-I might thus also reduce the activity of these enzymes; however, it is unlikely that apoC-I interacts with SCD1, FAR1 or FAR2, or enzymes that exhibit wax synthase activity, because these enzymes are integral intracellular membrane proteins (35, 3943) and apoC-I is secreted from cells (18).
It has been speculated that lack of sebum and meibum production in APOC1+/+ mice is attributable to increased cholesterol levels in their skin, which might lead to cytotoxicity resulting in atrophy of sebaceous and meibomian glands (11). However, hemizygous APOC1+/0 mice, expressing similarly increased levels of cholesterol in the epidermis compared with their homozygous APOC1+/+ littermates, show less reduced levels of wax diesters and TG (10). APOC1+/0 mice did not show sebaceous gland atrophy but only reduced sebum production, with an appearance of the skin similar to that of wild-type mice (10). These results indicate that the lack of sebum production cannot solely be the consequence of high cholesterol levels in the epidermis, at least not upon apoC-I overexpression.
Because APOC1+/+ mice, but not scd1/, dgat1/, and acat1/ mice (11, 33, 35), exhibit skin lesions containing extensive infiltration of macrophages into the epidermis (10), additional factors may play a role in the cutaneous abnormalities of APOC1+/+ mice. We recently showed that apoC-I augments the inflammatory response induced by LPS injections or inoculation with Klebsiella pneumoniae (12). As sebum is suggested to prevent bacteria from persisting in the hair canal, and APOC1+/+ mice lack sebum production (10), apoC-I may augment the inflammatory response to those bacteria, resulting in the influx and activation of macrophages and, thus, the inflammatory phenotype of the skin. In addition, extracellular FFAs associated with apoC-I may bind to the Toll-like receptor 4 and thereby induce the activation of the nuclear factor
B pathway (43, 44).
Thus, the expression level of human apoC-I in mice correlates positively with plasma FFA levels, and human apoC-I expression reduces adiposity and the production of sebum and meibum. Meibomian gland dysfunction in mice is a condition similar to dry eye syndrome in humans (11), and meibomian and sebaceous glands are commonly affected together in humans. Meibomian keratoconjunctivitis is frequently associated with sebaceous gland diseases such as seborrhoea sicca (45). Thus, it would be interesting to determine whether apoC-I plays a causal role in these diseases and also in obesity in humans.
Collectively, we conclude that binding of apoC-I to FFA accounts for the reduced uptake and subsequent esterification of FFA in cells. In addition, the physical association between apoC-I and FFA may result in a reduction of LPL activity by product inhibition, further reducing the availability of FFA. As a consequence, meibum and sebum production and the development of obesity are reduced in mice that overexpress human apoC-I.
| ACKNOWLEDGMENTS |
|---|
Manuscript received January 17, 2007 and in revised form March 2, 2007.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. M. Hofmann, D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschop, and D. Y. Hui Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E Deficient Mice Diabetes, January 1, 2008; 57(1): 5 - 12. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK |